Yag Protocol

GentleYAG Family of Laser Systems Treatment Guidelines Models : 9914-0950, 9914-0960, 9914-1020 and 9914-1030

8502-00-0867 Revision E Candela Corporation Proprietary Page 1 of 10

July 2006

These guidelines were developed from clinical experience and are subject to change as additional experience is gained. Be sure to inquire with your Candela Sales Representative, Clinical Consultant or visit MyCandela.com regularly for the latest updates and a comprehensive bibliography list of references/published articles. Treatment Guidelines do not take the place of the procedures and instructions found in the Operator’s Manual. FAILURE TO USE THE LASER IN ACCORDANCE WITH SUCH PROCEDURES AND INSTRUCTI ONS COULD RESULT IN SERIOUS INJURY TO THE OPERATOR, THE PATIENT AND OTHERS, AS WELL AS DAMAGE TO THE LASER SYSTEM . Follow OSHA and ANSI standards for laser safety. Protective eyewear must be worn by all persons in the treatment room during laser operation. .Perform User Verification tests as outlined in Section 6 of the Operators Manual at the start of each treatment day and when the hand piece is changed. Check the delivery system for any damage (ie: dropped). Discontinue use of your laser delivery sys tem if you suspect a problem.

HAIR REMOVAL/PFB TREATMENT PARAMETERS

For Skin Types I -VI

PT. SKIN

TYPE/ETHNIC ORIGIN

Spot

Size

(mm)

Pulse Duration

(ms)

FLUENCE

(J/cm 2)

COOLING*

DCD Spray/Delay

(ms)

RETREAT COMMENTS

I

Scandinavian

II

Northern European

(Caucasian)

8

10

12

15

18

3, 10, 20

90-100

70-80

60–70

40-44

26-30

III

(Dark Caucasian, Light Asian)

8

10

12

15

18

3, 10, 20

80-90

50-70

40–60

30-40

24-30

IV

(Mediterranean

Asian, Hispanic)

8

10

12

15

18

3, 10, 20

60-70

40-50

20-46

20-30

14-20

30/20/0

40/20/0

DCD spray duration and delay may be adjusted

to accommodate patient comfort

Do not use post laser pulse DCD cooling for

hair removal

DCD settings set too high or too low may cause pigmentary

problems. Lower DCD setting on darker skin

types

Facial: 4-6 weeks

Trunk: 6-8 weeks

Leg: 8-12 weeks

Cold compress or cold gel packs may be applied after treatment to cool skin and remove heat

Test small area and wait several minutes to evaluate response prior to treatment.

1.Establish skin type

2.Select pulse duration

short= finer hair

long = thicker hair

3. Select fluence based upon skin type.

Look for perifollicular edema

Increase fluence in a 2 J/cm2 increment until this response is seen.

Balance between laser heating and DCD cooling is critical.



July 2006

HAIR REMOVAL/PFB TREATMENT PARAMETERS

For Skin Types I -VI (Continued)

PT. SKIN

TYPE/ETHNIC ORIGIN

SPOT SIZE (mm)

Pulse Duration

(ms)

FLUENCE

(J/cm 2)

COOLING*

DCD Spray/Delay

(ms)

RETREAT COMMENTS

V

(Middle Eastern, Latin, Lighter

African-American, Darker Hispanic,

Indian, Native AM)

8

10

12

15

18

3, 10, 20

50-60

30-50

18–30

10-30

6-20

VI

(Dark African-American)

8

10

12

15

18

3, 10, 20

40-50

30-40

18-30

6-30

6-18

30/20/0

40/20/0

DCD spray duration and delay may be adjusted to

accommodate patient comfort

Do not use post laser pulse DCD cooling for

hair removal

Facial: 4-6 weeks

Trunk: 6-8 weeks

Leg: 8-12 weeks

Cold compress or cold gel packs may be applied after treatment to cool skin and remove heat

Test small area and wait several minutes to evaluate response prior to treatment.

1.Establish skin type

2.Select pulse duration

short= finer hair

long = thicker hair

3. Select fluence based upon skin type.

Look for perifollicular edema

Increase fluence in a 2 J/cm2 increment until this response is seen.



July 2006

VASCULAR TREATMENT PARAMETERS :

Lesion SPOT SIZE (mm)

Pulse Duration

(ms)

STARTING

FLUENCES

(J/cm 2)

COOLING*

DCD Spray/Delay

(ms)

Original Style Handpiece

COOLING*

DCD Spray/Delay

(ms)

New Style Ha ndpiece

CLINICAL ENDPOINTS &

RETREATMENT

IF CLINICAL ENDPOINT NOT

ACHIEVED:

Telangiectasia

Leg Vessel s

< 0.5mm

< 1 mm

20-40

40-60

Start with 360

Single pulse only

(No stacking or multiple passes)

Start w ith 220

Single pulse only


1.5 mm:

-50 ms spray/30 ms delay

-10 ms post spray

3mm:


-10 ms post spray

1.5 mm:


-10 ms post spray

3 mm:

-15-20 ms spray/20 ms delay

-10 ms post spray

Clinical endpoint vasoconstriction,

vasospasm and/or darkening of vessel

contents

-----

Evaluate/Retreat

8-10 weeks apart

Post treatment

Cold compress or cold gel packs may

be applied after treatment to cool skin and remove

heat

1. Decrease pulse width.

2 Increase fluence incrementally until desired result is achieved up to a maximum of 320J/cm 2 with 3mm spot size and up to 500J/cm 2 with 1.5mm spot size.

No post spray should be used on skin types IV - VI

.

.

1.5

3



July 2006

VASCULAR TR EATMENT PARAMETERS: (continued)


Pulse Duration

(ms)

STARTING

FLUENCES

(J/cm 2)

COOLING*

DCD Spray/Delay

(ms)


COOLING*

DCD Spray/Delay

(ms)

New Style Handpiece


RETREATMENT


ACHIEVED:

Telangiectasia

Leg Vessels

< 1.5 mm

40-60

Start with 2 00

Single pulse only


3mm:


-10 ms post spray

3mm:


-10 ms post spray

Clin ical endpoint vasoconstriction,


contents

Evaluate/Retreat

8-12 weeks apart



heat

Increase fluence incrementally until desired result is achieved up to a maximum of 280 J/cm 2


3



July 2006

VASCULAR TREATMENT PARAMETERS: (continued)


Pulse Duration

(ms)

STARTING

FLUENCES

(J/cm 2)

COOLING*

DCD Spray/Delay

(ms)


COOLING*

DCD Spray/Delay

(ms)

New Style Handpiece


RETREATMENT


ACHIEVED:

Telangiectasia

Leg Vessels

1.5-3.0 mm

60

Start with 180

Single pulse only


3mm:


-10 ms post spray

3mm:

-15ms spray/20ms delay

-10 ms post spray



contents

Evaluate/Retreat

8-12 weeks



heat

Increase fluence incrementally until desired result is achieved up to a maximum of 260J/cm 2


3



July 2006

VASCULAR TREATMEN T PARAMETERS: For skin types I -IV only (continued)


Pulse Width

(ms)

STARTING

FLUENCES

(J/cm 2)

COOLING*

DCD Spray/Delay

(ms)


COOLING*

DCD Spray/Delay

(ms)

New Style Handpiece


RETREATMENT


ACHIEVED:

Telangiectasia

Facial Vessels <.5 mm 0.5-1.0 mm

20

40

Start with 340

Single pulse only


Start with 250

Single pulse only


1.5 mm


-10 ms post spray

1.5 mm:

-10 ms/20 ms delay

-10 ms post spray


vasospasm, and/or

darkening vessel contents

Evaluate/Retreat

6-8 weeks

Cold compr ess or cold gel packs may


heat

Do Not Use 3 mm spot size on the face

Increase fluence incrementally until desired result is achieved up to a maximum of 400J/cm 2


1.5

1.5



July 2006

Skin Tightening /Wrinkle Reduction

Area

Spot Size (mm )

Pulse Duration

(ms)

Fluence

(J/cm2)

DCD Retreat Comments

(ms)

Face & Neck 10 50 50 40/20/0 4-5 TX performed monthly see below

Forehead 10 50 40-50 40/20/0 4-5 TX performed monthly see below

• Single pulsing with minimal overlap ( = 20%).

• Multiple passes (2 -3) are required at above settings to achieve collagen contrac tion.

• Treat face in sections (for example; first , three passes on the left cheek, the n the right cheek, then the forehead ).

General Guide lines for all Laser treament s:

Consult the Clinical In -service Manual for additional information, including contraindications and possible adverse affects.

Conduct a patient consultation complete with medical history prior to treatment.

Skin Preparation

• Clean and dry the skin thoroughly including removing all topic agents prior to treatment.

• Shave area to be treated thoroughly prior to treatment,

• Do not treat long hair, external hair may act as a heat sink and possibly burn the skin.

• Patients should not tweeze, wax, or have electrolysis 6 weeks before treatment.



July 2006

Test Areas

• Perform test areas when a concern exists regarding the potential response to treatment.

• Select a small area in the anticipated treatment site

• Apply a series of pulses with several fluences.

• Evaluate the sites in 2 weeks

• Treatment may proceed when the expected treatment response is noted.

Treatment Considerations : • Ensure that proper protective eyewear is in position prior to treatment.

• Do not treat skin within the orbital rim. • The distance gauge should be held at a perpendicular angle to the skin (90 degrees).

• The distance gauge rim should be in contact with the skin.

• Apply single pulses without overlap.

• Perform 3 consecutive passes.

• Perform a consecutive vertical, horizontal then diagonal pass to treat confluently and avoid “skip” areas.

• 40 J/cm2 may be used on the forehead if 50 J/cm2 is not tolerated.

• The use of epidermal cooling reduces the rise in temperature in the epidermis, allows for higher tolerated fluences, and provides partial anesthesia. Candela rec ommends the use of the Dynamic Cooli ng Device which delivers doses of cryog en selected by the user . The Dynamic Cooling Device (DCD) also contains an optional Post Spray feature. This feature provides additional cooling and may enhance p atient comfort if needed. When using the Post Spray feature, the user should start at low settings, observe patient response, and adjust if needed.

Treating Specific Body Areas

• CANDELA does NOT recommend treating the area within the orbital rim as ocula r damage may occur.

• Insert moistened white gauze cotton in nose or ears during treatment to prevent laser absorption by unintended targets.

• Patients with dental work may experience sensitivity when the laser pulse is administered in the perioral area; place moistened dental roll or moistened white

gauze between the teeth and the inside of the lip during treatment to prevent damage to the teeth or oral mucosa.

• Cover any area requiring shielding with moistened white gauze or a moistened white card to prevent absorption of light.



July 2006

• Use a white makeup pencil for drawing in a treatment area grid.

• When treating anal area, place wet gauze over the anus first. Methane gas is flammable.

Post -Treatment Care

• Cool compresses or cold gel packs may be applied to decrease edema and discomfort.

• A moisturizing SPF 30+ sunblock should be applied before the patient leaves the office.

• Avoid irritation of the treatment area.

• Resume usual topical agents when irritation resolves.

Expected Responses:

Laser Hair Removal:

• Perifollicular edema/erythema, uticaria

• The appearance of perifollicular edema and erythema may be altered if a topical anesthetic is used, as the topical may cause vasoconstriction or erythema

• After laser hair reduction (LHR), the treated hair may not shed for several weeks. Patient should be reassured that the hair will eventually exfoliate.

• Approximately 20% reduction of hair growth noted 4-8 weeks following each procedure.

Vascular lesions :

• Vasoconstriction of facial and leg veins, transient urticaria.

• Gradual fading over several weeks to months.

Untoward Responses

• LHR and Vascular lesions:

• Burning, blistering, scabbing, crusting, hyperpigmentation, hypopigmentation, purpura and/or herpes simplex activation—in rare cases, scarring may result

• Hypo- or hyperpigmentation may not appear for 1-2 weeks and in rare cases may last for months or longer.

• If hypo- or hyperpigmentation occurs treatment should not be performed until pigmentation returns to normal.

Determining the end of treatment

• Multiple treatments over a period of several months may be required.



July 2006

• The provider’s judgement will determine the end of treatment. Treatment should cease when the desired clinical endpoint has been achieved.

• Maintenance treatments may be required to maintain the desired response .

Reduction of Plume and Hair Odor in Treatment Room

• Use a smoke evacuator during treatment especially for treatment of larger areas.

• Wear a laser mask to reduce breathing plume.

• Keep room well ventilated to disperse hair odor.

SPECIAL CONSIDERATIONS WHEN USING DCD CRYOGEN SPRAY: Do NOT Spray Cryogen into the eyes or into an open wound. The DCD spray should be sufficient to cover the spot on the skin and provide epidermal cooling in opposition to the heat generated from the laser. It is important to maintain both skin protection and patient comfort, so adjust the spray parameters accordingly, keeping in mind the patient’s skin type. Begin with suggested guidelines and increase or decrease settings based on the skin reaction and the patient’s tolerance . Increasing cryogen spray durations does not equate to increased epidural protection in all skin types, especially darker skin types.

WARNING When treating patients with the GentleYAG laser and using the Dynamic Cooling Device (DCD) in conjunction with E CG monitoring device attached to the patient, interference with the ECG monitoring device may result.

CAUTION A buildup of frost may occur on the distance gauge during extended tr eatments. Wipe the distance gauge with a warm moist cloth to prevent accumul ation of frost.

CAUTION If crescent shaped marks, welts or wheals are noted during treatment, the fluence and or DCD settings should be adjusted immediately. Not making such an adjustment can result in subsequent crusting blistering and other adverse react ions. Crescents may result from not holding the distance gauge properly. If problem persists, discontinue treatment and refer to user verification test section of the Operator’s Manual.

CRYOGEN REORDER - Replacement canisters of cryogen are ordered by the part number. Candela GentleCooltm canisters sizes are available in 1000 grams

only for this product: 12 canisters/case #1600-00-0212

CAUTION Do not use Flammable products on the skin or in the vicinity of the laser.

Candela Vbeam Perfecta, Platinum, Aesthetica Treatment Guidelines

8502-00-0891 Revision 07 Candela Proprietary Sheet 1 of 10

Approval of Clinical Parameters

By Dr.Robin Stones

In Compliance With Standard P1.1 For Prescribed Techniques and Prescribed Technology

Dealing With Contradictions And Complications For

Candela VBEAM PEERFECT

And

Candela GentleLaserscope Class VI – Lyra and Aura Lasers

Revision :As per published protocols Issue date: October 2007 Review Date: September 2009 Issued by: Alex Zarneh (unless laser software / hardware is upgraded or clinical reasons justify amendment)



Lesion Spot size (mm)

Pulse Duration (ms)

Fluence (J/cm2)

DCD Spray / Delay

(ms)

Retreat (weeks)

Comments

Telangiectasia Facial Nasal

5 7 10 3x10

5, 7 10 3x10

6,10,20 6,10,20 6,10,20 10 40

7.5-12 7-12 5.5-7.5 11-14

8-12 6.5-7.5 10-12

medium 30/20

4-6

Double or triple pulse depending on the refill of the vessel. Use 3x10 on linear vessels. For vessels which do not clear immediately: treat first with the round spot followed by the 3x10 spot. Use of shorter pulse durations will induce purpura but may clear vessels faster.

Leg

3x10

10,20,30,

---------- 40

11-18

------------

15-25

medium 30/20 -------------

high 40/20

8-12

Select longer pulse durations to decrease purpura.

Telangectatic Matting

7 10

10,20,30

11-15

6-7

medium 30/20

6-10 Larger spot size may improve results. Expect erythema.



Photo- Rejuvenation Wrinkles Diffuse Facial Telangiectasia Rosacea Dyschromia Benign Epidermal Pigmented Lesions

7

10

---------- 7 10

12

--------- 7

10

---------

7PL 10PL

10 6

---------

6,10,20

40 ------------ 10 ----------- 1.5

7 6

-----------

8-11 5.0 -7

5-7 ------------- 7-8 5-7 ------------- 7-10 5.5-8

medium 30/20

-------------- OFF

4 – 6

Treat full face with one pass using dyschromia parameters followed by an additional pass using wrinkles/diffuse redness parameters. Diffuse vessels/background blush:may treat the entire cosmetic unit w/ 50% overlap using a larger spot. Shorter pulse durations and higher fluences may induce purpura. Vessels may be pulsed 2-3 times to obtain transient intravascular purpura, which will disappear and become bluish pink”dusky erythema.” May use 10-12mm spot then retreat larger vessels immediately with smaller spot size. --------------------------------------------- Press the lens firmly onto the skin until the skin turns pale.

Clinical endpoint = darkening or color change at the treatment site- observe tissue response..Always start with the lowest fluence and observe the lesion for several minutes before adjusting fluence.Darker lesions may require lower fluences. Peri-lesional erythema may occur.

Poikiloderma of Civatte

10

10

5-6.5

medium 30/20

4-6

Always perform test spots laterally. Apply pulses close to one another to minimize uneven pattern. Feather edge(decrease fluence by 1-2 J/cm2 @ periphery) to minimize sharp line of demarcation. Expect erythema

Cherry Angioma; Spider Angioma

3 5 7 10

1.5

12 10

8-11.5 5-10

medium 30/20

4-6 Use white, moist template to isolate lesion. Double pulse center of angioma first, then treat peripheral vessels.Clinical endpoint=purpura.



Hemangiomas 5 7 10

1.5 8-10

6-10

5-6

medium 30/20

high 40/20 for larger, thicker lesions

2 weeks (neonate and

Infant) 8-12 weeks (Adult)

Use caution and lower fluences for neonates and infants. Treat proliferative hemangiomas every two weeks.Improper treatment may cause scars. Refer to specialist if not within your typical practice.Clinical endpoint=purpura.

Venous Lake 7

1.5

7-10

medium 30/20

4-6

Two treatments may be required. Clinical endpoint=purpura.

Port Wine Stains Facial Neck, Head Trunk, Extremities Hypertrophic PWS

5 7 7 10 5 7 10 5 7 10

0.45

1.5

1.5

1.5

10-15

8-12 4-7.5

6-12 6-7.5 5-7

10-15 10-15 10

medium 30/20

medium 30/20

high 40/20

8-12

Use caution lower fluences and DCD for neonates and infants. Clinical endpoint= purpura Use lower fluences on neck and extremities. Ectatic vessels associated with hypertrophic PWS may be double pulsed.

Warts Non- Facial ---------------------- Facial

5 7

---------- 5

1.5

----------

1.5

12-15

------------

9-9.5

0

----------

medium 30/20

2-3

Non-Facial Warts: Pare thick warts before treatment. Cryogen may be sprayed pre and post laser to cool area. Topical or injected anesthetic may be utilized. Pulse stack (1-3 pulses) if tolerated. Clinical endpoint= purpura. Treat a 1-2 mm margin of uninvolved skin with single pulses at the periphery of the wart. Use of home topical therapy may increase efficacy.

Facial Warts:CAUTION: Single pulses only Observe tissue response Use DCD

Inflammatory Acne Vulgaris

10

3

4.5

medium 30/20

4

Slight redness and light purpura may be experienced, observe closely.

Scars 7 --------

10

.45, 1.5

7-8 -----------

4-5

medium 30/20

4-6

Treatment may begin after suture removal. Newer more vascular scars may respond better than older,atrophic scars. Clinical endpoint=erythema- purpura.



Striae 10

0 .45

3-7

medium 30/20

4-6

Newer more vascular striae may respond better than older, atrophic striae. Clinical endpoint=erythema- purpura

Benign Cutaneous Vascular Gynecological Lesions including Vulvodynia

7

0.45

5-6

medium 30/20

8

Clinical endpoint is light purpura,

Psoriasis 5 7 10

0.45,1.5

6-8 4-8 3-8

optional, may use 30/20 for patient comfort

2-4 May require several treatments. Remove scale prior to treatment.Clinical response =purpura.

BOLD SETTINGS ARE DISPLAY SCREEN DEFAULT PARAMETERS FOR: Vbeam Perfecta, Platinum, Aesthetica SPECIAL CONSIDERATIONS WHEN USING DCD CRYOGEN SPRAY:

SELECT MEDIUM (30/20) DEFAULT SETTING ADJUST BASED UPON EPIDERMAL RESPONSE AND PATIENT COMFORT. The use of epidermal cooling is strongly recommended. Cooling reduces the rise in temperature in the epidermis, allows for higher tolerated fluences, and provides partial anesthesia. Do NOT Spray Cryogen into the eyes or into an open wound. The DCD spray should be sufficient to cover the treatment area and provide epidermal cooling in opposition to the heat generated from the laser. It is important to maintain both skin protection and patient comfort. Begin with suggested guidelines and increase or decrease settings based on the skin reaction and the patient’s tolerance. Darker skin types do not tolerate excessive amounts of DCD spray. Use caution when increasing DCD spray time on darker skin types. Pre and post cooling with a cold compress may be beneficial.

SPECIAL CONSIDERATIONS WHEN DCD CRYOGEN SPRAY IS OMITTED: If the Dynamic Cooling Device Option is not utilized and cooling is desired, another method of cooling (air cooling or contact cooling, etc) should be utilized. Several applications ( non-facial warts, benign epidermal pigmented lesions) are treated without DCD cryogen spray.

Application of a cool compress following the treatment may be desired in this situation.



A. Pre Treatment Preparation 1. Pretreatment visit

Patient selection should be based upon the physician’s assessment of the individual patient. including a detailed medical and medication history. The treatment protocol should be discussed in detail including risks & benefits side effects and expected results, alternative or concurrent therapies and follow up care. The physician should set proper expectations based upon their clinical experience. Informed consent and photographs should be obtained. Individual patient characteristics such as skin condition and type, sex, age and medications may influence the response to and efficacy associated with treatment. The response to treatment may vary on subsequent visits and the skin reaction must be carefully assessed on each visit. These guidelines are intended for use by providers who are knowledgeable in laser tissue interactions.

2. Contraindications and Precautions

a. Accutane: Wait 6 months after the completion of Accutane therapy b. Tattoos: Do not treat tattooed skin, including decorative, permanent makeup and

radiation port tattoos.

c. History of photosensitivity to 595 nm light

d. Pregnancy: Refer to Candela Corporation policy # 0920-23-0814.

e. Seizure disorders: Do not treat patients with a history of light-triggered seizures.

f. Medications: Daily anticoagulation therapy, iron supplements, herbal supplements such as ginko,ginseng or garlic may bruise more readily.

g. Photosensitizing Medications: Medications that induce photosensitivity or medications

within or above the 595 wavelengths. Refer to Candela Corporation Drugs That May Cause Photosensitivity. Stop the medication if possible for 3-5 days prior to treatment.

h Topical Medications and skin care products: Stop 72 hours pre and post. Self tanning

products must be removed. i. Herpes Simplex Virus (HSV) 1 & 2:Do not treat if active lesion(s) are present within the

intended treatment area. Patients with a known history of frequent HSV 1&2 lesions should begin prophylaxis prior to treatment as prescribed by their physician.

j. Poorly controlled Medical Conditions: These patients should be carefully evaluated by

their physician for medical clearance. k. Active skin infection: Avoid treatment of open wounds and skin that is actively infected.

l. Cold sensitivity: Use caution when treating patients with Raynaud’s phenomenon.

m. Keloid scarring: Perform test spots prior to treating larger areas.

n. Implanted medical devices: Pacemakers, cardioverters and other implantable devices or fillers: consult MD.

o. Sunburn: Postpone treatment for 10-14 days after acute unprotected sun exposure.



3. Skin Preparation for Treatment

a. Topical anesthetics may be used prior to laser treatment per manufacturers’ directions. HOWEVER, the topical anesthetics should be removed from the skin prior to treatment.

b. Skin must be clean and dry; remove all lotions, perfumes, make-up, deodorant, self

tanners, etc.

c. Candela does not recommend the use of alcohol to clean the skin prior to treatment.

Rinse the treatment area thoroughly with water after cleaning with soap (or similar mild

cleanser) and water.

d. Shave hair-bearing areas prior to treatment.

4. Test Areas

a. Perform test areas when a concern exists regarding the potential response to treatment.

* Select a small area in the anticipated treatment site

* Apply a series of 1-3 pulses with several incremental increased fluences.

b. Evaluate the sites in 2 weeks

c. Treatment may proceed when the expected treatment response is noted.

B. Procedure for establishing the Purpura – Free Threshold 1. Select spot size, pulse duration, fluence and DCD settings.

2. Apply escalating fluences until purpura appears, then reduce the energy by 0.25- 0.50 J/cm2.

3. Optimum parameters may be achieved by matching pulse duration to vessel size.

Note: Treatment at sub-purpuric fluences may necessitate additional treatments for complete clearance of vessels on the face. C Laser Treatment Considerations

1. Perform User Verification Tests prior to each treatment session. This test procedure is outlined in the Operator’s Manual.

2. Position patient comfortably and confirm that the patient and everyone in the treatment

room are wearing the correct protective eyewear.

3 Always hold the laser handpiece perpendicular to the skin to apply laser energy,

otherwise an uneven application of cryogen and energy may occur and an untoward skin

reaction may occur.



4. The aiming beam and laser beam are dimensionally identical, so the aiming beam can

be used to accurately define the treatment area. The spot should be absolutely circular if

the handpiece is held at the appropriate 90 degree angle.

5. Always observe the epidermal response throughout the treatment and adjust the fluence

and DCD as needed.

6. Measures to prevent untoward effects and decrease discomfort

Cool compress or cold gel packs may be applied immediately before, during and after

treatment to decrease discomfort.

Large areas that are divided into sections need to be cooled just prior to treatment

After each laser pulse, a gentle rub of the area with a gloved hand may minimize

discomfort.

7. Treating Specific Body Areas

Upper and lower eyelids may only be treated following the insertion of intraocular corneal

eye shields.

Insert moistened white gauze cotton in nose or ears during treatment to prevent laser

absorption by unintended targets.

Patients with dental work may experience sensitivity when the laser pulse is administered in

the perioral area; a moistened dental roll or moistened white gauze between the teeth

during treatment to prevent unintentional treatment of adjacent tissue..

Cover any area requiring shielding with moistened white gauze or a moistened white card

to prevent absorption of light. Refer to the Laser Accessory Vendor sheet for additional

product information.

Use a white makeup pencil for drawing in a treatment area grid.

When treating anal area, place wet gauze over the anus first. Methane gas is flammable.

8. The Cleaning and Disinfecting Policy is outlined in Section 6 of the Operator’s Manual.

Follow the procedures outlined in the distance gauge cleaning protocol to prevent build

up of debris on the distance gauge and to maintain good visibility.

The Compression Handpiece Distance Gauge Cleaning and Disinfecting Policy is located

in Section 6.



D. Post-treatment care

1. Cool compresses or cold gel packs or chilled aloe vera gel may be applied after

treatment

2. A moisturizing SPF 30+ sunblock should be applied per manufacturer’s instructions to

sun-exposed areas prior to the next treatment.

3. Clean the area gently and avoid irriation from friction or rubbing.

4. Resume use of usual topical agents when any irritation resolves.

E. Expected Responses

1. Purpuric Treatment: purpura, edema, minimal to moderate discomfort relieved by cold

compress or cool gel pack. 2. Non-Purpuric treatment: edema, erythema, and a tight sensation with minimal

discomfort. F. Untoward Effects

Itching(hive-like response)

Burning, blistering, scabbing, crusting, color and/or texture changes

Herpes simplex activation

Hyperpigmentation( darkening of the skin, transient or long term)

Hypopigmentation( lightening of the skin; transient, long term or possibly permanent)

If hypo- or hyperpigmentation occurs treatment should not be performed until

pigmentation returns to normal.

Scarring (rare, possibly permanent)

G. Determining the end of treatment

1. Multiple treatments over a period of several months may be required.

2. The provider’s judgment will determine the end of treatment. Treatment should cease

when the desired clinical endpoint has been achieved.

3. Maintenance treatments may be required to maintain the desired response .

H. Additional Warnings and Precautions

CAUTION A buildup of frost may occur on the distance gauge during extended treatments. Wipe the distance gauge with a warm moist cloth to prevent accumulation of frost



CAUTION

If crescent shaped marks, welts or wheals are noted during treatment, the fluence and or DCD settings should be adjusted immediately. Not making such an adjustment can result in subsequent crusting blistering and other adverse reactions. Crescents may result from not holding the distance gauge properly. If problem persists, discontinue treatment and refer to user verification test section of the Operator’s Manual.

CAUTION Do not use Flammable products on the skin or in the vicinity of the laser.

Warning When using the Vbeam laser with the Dynamic Cooling Device (DCD) in use in conjunction with an ECG monitoring device interference with the ECG monitoring device may result.

Warning Oxygen will accelerate combustion of any flammable material. Never direct oxygen (with or without gasses) toward or over the laser field. Extreme caution should be used. When oxygen is in use, gauze, sponges, and hair near the treatment area should be moistened with water. Be aware that hairspray, gel, deodorants, and other grooming products may contain flammable substances.

Caution

Treatment to areas bearing hair may cause the hair to be singe and may cause it to ignite. A fire extinguisher should be available.

Documents

Yag Protocol